Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic Boosts Full-Year 2021 Revenue Guidance by 10 Percent

NEW YORK – SomaLogic on Monday said that it expects to exceed its previous full-year 2021 guidance of $66.7 million in revenues by 10 percent or more.

In a statement, SomaLogic CEO Roy Smythe said that in the first half of 2021 the company "exceeded our expectations with stronger revenue, better gross margins, faster commercial team ramp, and above-plan clinical partnerships."

SomaLogic in March entered into an agreement to merge with CM Life Sciences II, a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital and Corvex Management, with the purpose of listing on the Nasdaq Global Market. The merger is expected to close in the third quarter.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.